BMI1+ CSCs have increased AP-1 activity and are cisplatin-resistant, and combination therapy that targets BMI1+ CSCs and the tumor bulk yields better outcomes and effectively prevents metastasis [99]. The gene discussed is BMI1; the disease is neoplasm.